Please assess the completion status of the following clinical trial:

Trial Title: Nandrolone Decanoate in the Treatment of Telomeropathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral blood leukocytes telomeres short for age, below the first percentile of a curve based on 500 healthy individuals between 0 and 100 years, with or without a telomerase gene mutation.~AND~* One or more of the following cytopenias:~Anemia (symptoms of anemia with hemoglobin \<9.5 g/dL, or need for transfusion \> 2 units of packed red blood cells/month for at least two months, or absolute reticulocytes count \<60.000/μL).~Thrombocytopenia (platelets counts \<30.000/μL or \<50.000/μL associated with bleeding, or megakaryocytes reduction in the bone marrow).~Neutropenia (absolute neutrophil counts \<1.000/μL).~OR~* Idiopathic pulmonary fibrosis diagnosed according to the American Thoracic Society (ATS) criteria.~Exclusion Criteria:~* Terminal disease or liver disease, renal, cardiac, neurological, infectious or concomitant metabolic state whose gravity prevents the ability of the patient to tolerate the treatment protocol, or probable death within 30 days.~* People with cancer who are undergoing chemotherapy.~* Pregnancy, or desire to not prevent pregnancy in childbearing age.~* Aplastic Anemia patients with indication for bone marrow transplantation and matched donor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Nandrolone Decanoate (Type: EXPERIMENTAL): Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).